Persistent infection with high-risk HPV (hrHPV) types is the known cause of cervical cancer (1), a neoplasia suitable to effective primary and secondary prevention. For many decades cervical cancer screening has been performed by cytology as the primary test, with significant reductions in cancer incidence (2), and more recently, the use of hrHPV testing with cytology triage in large randomized controlled trials (RCTs) has been demonstrated more effective than cytology in preventing invasive cervical cancer (3). The aim of screening is the prevention of cervical cancer through detection and excision of precursor lesions (namely, CIN2 and worse), and its effectiveness, besides primary test performance, depends on target population coverage and adherence to quality-controlled protocols; organized population-based screening is more cost-effective than opportunistic testing.
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HPV-based screening is more sensitive than cytology-based screening given the use of clinically validated tests for hrHPV types (4), in women 30-yrs and older, and triage of HPV-positive cases to counterbalance the 2.5-4% lower specificity (3). HPV infection is transient in the vast majority of the women (and particularly in those younger than 30-35 years of age) and only a minority harbour a persistent infection and have or are at risk of having a high-grade lesion (5) . Spontaneous regression of CIN2 and, to a lesser extent, CIN3 lesions also occurs in a proportion of women, and is more frequent in the youngest. Therefore, triage is necessary to select the women at higher risk of precancer who need immediate colposcopy, thus limiting excessive referral and overdiagnosis in women with transient and not (or less) clinically relevant HPV infections. Cytology is actually the most widely used test to triage hrHPV-positive women attending organized screening (6), but search for alternative (and less subjective) tests is advocated. Several studies, investigating p16 expression, HPV genotyping, HPV mRNA expression, methylation of cellular and/or viral sequences as triage markers (used alone or in combination) have been published so far (7) (8) (9) (10) (11) (12) .
These markers have been analyzed in terms of immediate or subsequent risk of CIN2+ or CIN3+, sensitivity, specificity, positive predictive value, and cost-effectiveness (colposcopy referrals, overdiagnosis, harms). These analyses have been performed on different populations (clinical settings or population-based screening), of different ages, cross-sectionally only or longitudinally.
Overall, HPV16 has always been associated with the highest risk of CIN2+ and CIN3+, with a three-tier ranking of the other hrHPV types; risks were highest in the first screening round, gradually decreasing over time but still persisting after more than 9 years (12). Moreover, an inverse relationship between sensitivity and specificity of the triage tests was always registered, and different combinations have been proposed. Indeed, the ideal triage test/strategy should allow selection of women at highest risk to be immediately referred to colposcopy, while referring the other hrHPV-positives to a follow-up step that will later allow additional risk stratification. Longitudinal data from RCTs on persistently HPV16-positive women with no lesions detected should also be evaluated to define their long-term risk and best follow-up strategy before implementation of triage by partial genotyping. Finally, in the screening context two additional caveats must be kept into consideration in the near future; namely, the different risk of precursor lesions in the first versus the subsequent hrHPV-based rounds, much lower in the second (16) , and the screening strategy for vaccinated women, in whom lesions caused by types 16 and 18 will gradually disappear, and specific protocols will have to be designed.
